Javascript must be enabled to continue!
Review On Prodrug : An Advance Approach for The Drug Design to Enhance the Therapeutic Efficacy
View through CrossRef
Prodrugs are derivatives of drug molecules that are pharmacologically inactive but require either chemical or enzymatic transformation to release the active drug in vivo in order to exert a pharmacological effect. Prodrugs have better delivery properties that surpass the parent drug molecule. Prodrug concept is justified because it enables the active drug to overcome the barrier that would impede it from reaching the site of action to exert the required pharmacological activity. Some of the barriers that the prodrug approach helps to surmount are as follows, low bioavailability due to poor aqueous solubility (corticosteroids); poor permeability or absorption (ampicillin); high first pass metabolism (propranolol); metabolic instability leading to short half- life, (dopamine); poor site specificity (anticancer agents); incomplete absorption (epinephrine); unfavorable organoleptic properties (chloramphenicol); difficulties during formulation and adverse effects and toxicity. The prodrug approach is rapidly becoming a crucial part in the stratagem of delivery of drugs. The prodrug strategy implementation in the last 20 y has led to a steady advancement in the biopharmaceutical, physicochemical and/or pharmacokinetic attributes of the pharmacologically active compounds
Title: Review On Prodrug : An Advance Approach for The Drug Design to Enhance the Therapeutic Efficacy
Description:
Prodrugs are derivatives of drug molecules that are pharmacologically inactive but require either chemical or enzymatic transformation to release the active drug in vivo in order to exert a pharmacological effect.
Prodrugs have better delivery properties that surpass the parent drug molecule.
Prodrug concept is justified because it enables the active drug to overcome the barrier that would impede it from reaching the site of action to exert the required pharmacological activity.
Some of the barriers that the prodrug approach helps to surmount are as follows, low bioavailability due to poor aqueous solubility (corticosteroids); poor permeability or absorption (ampicillin); high first pass metabolism (propranolol); metabolic instability leading to short half- life, (dopamine); poor site specificity (anticancer agents); incomplete absorption (epinephrine); unfavorable organoleptic properties (chloramphenicol); difficulties during formulation and adverse effects and toxicity.
The prodrug approach is rapidly becoming a crucial part in the stratagem of delivery of drugs.
The prodrug strategy implementation in the last 20 y has led to a steady advancement in the biopharmaceutical, physicochemical and/or pharmacokinetic attributes of the pharmacologically active compounds.
Related Results
Recent Advances in Prodrug Approach over Conventional Drug Therapy
Recent Advances in Prodrug Approach over Conventional Drug Therapy
Background:
Prodrugs represent a strategically designed category of medicinal compounds
aimed at optimizing drug pharmacokinetics. By modifying the pharmacological action of the
dr...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Synthesis and in vitro kinetic study of new mutual prodrug for colon cancer associated with constipation
Synthesis and in vitro kinetic study of new mutual prodrug for colon cancer associated with constipation
Objective: a new mutual prodrug was synthesized for colon targeting in the treatment of colon cancer associated with constipation. Methods: a new mutual prodrug was synthesized thr...
Abstract 4157: Prodrug development of Cyclo-Creatine: Enhancing permeability and reducing toxicity for HER2+ breast cancer treatment
Abstract 4157: Prodrug development of Cyclo-Creatine: Enhancing permeability and reducing toxicity for HER2+ breast cancer treatment
Abstract
HER2+ breast cancer is an aggressive subtype of cancer that often develops resistance to the current first-line therapy, Trastuzumab. In our previous work, ...
Abstract 738: Design and synthesis of novel N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies
Abstract 738: Design and synthesis of novel N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies
Abstract
The over-expression of telomerase in cancer cells has been previously exploited for gene therapy strategies. One approach involves the use of a plasmid cont...
Photodynamic Therapy-Accelerated Hypoxia-Responsive Prodrug Release for Synergistic Photo-Chemotherapy of Melanoma Cancer based on Noncovalent Interactions
Photodynamic Therapy-Accelerated Hypoxia-Responsive Prodrug Release for Synergistic Photo-Chemotherapy of Melanoma Cancer based on Noncovalent Interactions
Chemotherapy plays a crucial role in clinical cancer treatment. However, it is confronted with dire challenges in achieving high specificity due to their indiscriminate interaction...

